Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 3Carcinoma, Transitional Cell 3Urethral Neoplasms 2Ureteral Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Recurrence 1Prostatic Neoplasms 1Penile Neoplasms 1Neoplasms 1Carcinoma, Small Cell 1Carcinoma 1Breast Neoplasms, Male 1

Interventions

Docetaxel 171Radiotherapy 144Magnetic Resonance Spectroscopy 142Leuprolide 112Prednisone 108enzalutamide 102Radiosurgery 101Abiraterone Acetate 94Androgen Antagonists 91Goserelin 83bicalutamide 81gallium 68 PSMA-11 70Surveys and Questionnaires 63apalutamide 57Specimen Handling 56acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 55Radiation 47Gonadotropin-Releasing Hormone 45Standard of Care 44Biopsy 44Brachytherapy 42Radiotherapy, Intensity-Modulated 40Blood Specimen Collection 40darolutamide 39abiraterone 39cabazitaxel 35Exercise 35Carboplatin 33Pluvicto 32Triptorelin Pamoate 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Prostatic Neoplasms × vinflunine × Clear all
NCT00545766 2021-12-16

Vinflunine in Hormone Refractory Prostate Cancer (HRPC)

SCRI Development Innovations, LLC

Phase 2 Completed
41 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡